US House sends drug bill to Senate for final vote

(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

Under the , approved by majority voice vote Wednesday, the FDA will have more flexibility to inspect sites in China, India and other countries. The number of U.S. drugs produced overseas has more than doubled over the last decade.

The underlying legislation renews an agreement under which companies pay the FDA to review new products. The FDA will collect $6.4 billion in fees from companies over the next five years. For the first time, the agency will collect fees from generic drugmakers to speed up approvals of their therapies. The FDA currently has a backlog of roughly 2,700 generic drugs awaiting review.

Other sections of the bill increase fines for drug counterfeiting and require drugmakers to notify the government earlier of potential drug shortages. More than 280 drugs are currently in short supply in the U.S., due in part to drug industry consolidation.

The bill sorts out differences in prior legislation passed by the House and Senate. House lawmakers approved their initial version of the sweeping legislation last month in a 387-5 vote.

The Senate is expected to vote on the bill next week, after which it will go to White House to be signed into law.

0 shares

Related Stories

Senate passes bill to boost food safety

date Nov 30, 2010

(AP) -- The Senate passed legislation Tuesday to make food safer in the wake of deadly E. coli and salmonella outbreaks, potentially giving the government broad new powers to increase inspections of food ...

US lawmakers reject Canada drug purchases

date Oct 20, 2011

The US Senate Thursday rejected a measure that would have enabled Americans to buy prescription drugs in Canada in a bid to reduce the costs of their health care.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.